Introduction {#s1}
============

Pancreatic cancer (PanCA) largely affects patients of advanced age; median age at diagnosis for adenocarcinoma is 71 years \[[@R01]\]. Age plays an important role in treatment decision-making \[[@R02]\]. Few studies have investigated the impact of age on treatment and outcome of PanCA.

The currently available data suggest younger PanCA patients are more likely to receive curative intent surgery and cancer directed surgery and may have better survival \[[@R03]-[@R05]\]. These reports may be limited by the fact that non-operative therapy, a key component of PanCA treatment, was not reported, and by the lack of treatment detail which is common in reports derived from national population datasets \[[@R06], [@R07]\].

Although younger patients may tolerate more aggressive therapy better, patients of increasing age may undergo aggressive treatment for pancreatic tumors with good outcome \[[@R08], [@R9]\]. Pancreatic resection with good outcome has been described in octogenarians; however, other studies have demonstrated that older patients have increased rates of complications \[[@R9]-[@R11]\]. Older patients may have significantly worse overall health at the time of treatment which can contribute to worse outcomes \[[@R11]\].

Few publications focus on age-related differences in treatment provided and overall survival (OS) for PanCA. We reviewed data from our cancer data registry to exam the hypothesis that young patients with PanCA would be treated more aggressively and therefore have better prognosis. We describe differences between treatment rendered and overall outcome between patients ≤ 50 years old and those \> 50 years old.

Methods {#s2}
=======

IRB approval was obtained to query the cancer database at the Ellis Fischel Cancer Center for patients diagnosed with PanCA from 1984 to 2008. Data collected included basic demographic data, histological tumor type, site of tumor, tumor grade, tumor stage, tumor size, number of positive lymph nodes (LNs) and treatment interventions, including chemotherapy, radiation therapy and surgical treatment. Age 50 was selected to dichotomize patient groups since this was the age approximately one standard deviation below the average age of patients in the study (63 years). Survival data were updated using publically available records (social security death index). Survival comparison was based on mean survival at last follow-up. Censoring was not used.

Statistical analysis {#s2a}
--------------------

Demographic data including age, gender and race are presented as mean ± standard deviation. Statistical analysis was performed with SPSS^®^ 18.0, IBM^®^ Corporation (Somers, NY). Continuous data were analyzed with Student's t test for independence, using alpha value of 0.05. Categorical data were analyzed using Chi-square test in cross-tabulation format. Statistical significance was considered at P value \< 0.05 for all statistical analyses.

Results {#s3}
=======

The mean age of the study population was 63.2 years (range 27 - 93 years). Patients \> 50 years old were more likely to have an exocrine cancer than those ≤ 50 years old (93% vs. 77%, P \< 0.001). The majority of patients had moderately differentiated adenocarcinoma, but there was not an association between age and tumor grade. There was no difference between age groups with respect to tumor size, tumor stage, or LN involvement. [Table 1](#T1){ref-type="table"} summarizes patient demographics and tumor characteristics.

###### Demographic and Tumor Characteristics for Pancreas Cancer Patients ≤ 50 Years Old and \> 50 Years Old

                            Age ≤ 50 years (%), N = 53   Age \> 50 years (%), N = 254   P value
  ------------------------- ---------------------------- ------------------------------ ----------
  Age                       44 ± 5.7                     67.2 ± 9.3                     \< 0.001
  Gender                                                                                
    Male                    33 (64)                      143 (57)                       0.372
    Female                  19 (37)                      109 (43)                       
  Race                                                                                  
    Caucasian               34 (92)                      158 (93)                       0.585
    African American        3 (8)                        9 (5)                          
    Other                   0 (0)                        3 (2)                          
  Location of tumor (%)                                                                 0.541
    Head of pancreas        34( 63)                      146 (58)                       
    Body/tail of pancreas   12 (23)                      59 (23)                        
    Unknown                 7 (13)                       49 (19)                        
  Exocrine tumor stage                                                                  0.516
    I                       3 (8)                        16 (7)                         
    II                      12 (30)                      53 (25)                        
    III                     8 (20)                       24 (11)                        
    IV                      17 (42)                      123 (57)                       

Regardless of tumor type, the rate of surgery was similar between age groups ([Table 2](#T2){ref-type="table"}); however, a higher number of patients ≤ 50 years old received chemotherapy as part of their treatment (62% vs. 41%, P = 0.005). Similarly, a greater number of patients ≤ 50 years old received radiation than older patients (28% vs. 15%, P \< 0.03). When all tumor types were considered, OS was 24.2 months for patients ≤ 50 years old, and 13.6 months for patients \> 50 years old (P = 0.06).

###### Treatment and Outcomes in Younger Versus Older Pancreas Cancer Patients

                              Age ≤ 50 (%)   Age \> 50 (%)   P value
  --------------------------- -------------- --------------- ---------
  Surgery                     11 (22)        51 (20)         0.911
  Chemotherapy                33 (62)        104 (41)        0.005
  Radiation                   15 (28)        39 (15)         0.025
  Number still alive          4 (8)          19 (8)          0.987
  Overall survival (months)   24.2           14              0.06

Patients with exocrine tumors were significantly older than those with endocrine tumors (64.1 years vs. 54.3 years, P \< 0.001) and as age increased, exocrine tumors were more common. Exocrine tumors were more likely to be located in the pancreatic head while endocrine tumors were more likely to be found in the pancreatic body or tail (62% vs. 44%, P = 0.001). Patients with endocrine tumors were more likely to undergo surgery than those with endocrine tumors (48% vs. 17%, P \< 0.001), but chemotherapy treatment was not different between these groups (38% vs. 46%, P = 0.44). Of the exocrine tumor patients, 20% underwent radiation therapy, whereas no endocrine tumor patients underwent radiation therapy. Exocrine tumor patients had significantly shorter mean survival than those endocrine tumor patients (10.9 months vs. 58.7 months, P \< 0.001). At last follow-up, only 4% of exocrine tumor patients were alive compared to 41% of endocrine tumor patients (P \< 0.001).

When endocrine and exocrine cancer treatment was considered by age group, there was no difference in rate of surgery ([Table 3](#T3){ref-type="table"}). Exocrine cancer patients ≤ 50 years old were more likely to undergo chemotherapy (68% vs. 42%, P = 0.001) and radiation therapy (37% vs. 17%, P = 0.003). There was no difference between age groups in terms of chemotherapy used to treat endocrine cancers. OS between ages was similar in patients with exocrine tumors, 9.6 months in younger patients versus 11.2 months in older patients ([Fig. 1](#F1){ref-type="fig"}). Endocrine cancer patients ≤ 50 years old did not have increased OS compared to older age group ([Fig. 2](#F2){ref-type="fig"}).

![Comparison of survival in patients younger than and older than 50 years old who were diagnosed with exocrine pancreatic tumors (solid line: patients ≤ 50 years old; dashed line: patients \> 50 years old).](wjon-05-007-g001){#F1}

![Comparison of survival in patients younger than and older than 50 years old who were diagnosed with endocrine pancreatic tumors (solid line: patients ≤ 50 years old; dashed line: patients \> 50 years old).](wjon-05-007-g002){#F2}

###### Age Comparison for Exocrine and Endocrine Tumors

  Patient population          ≤ 50 years (%)   \> 50 years (%)   P value
  --------------------------- ---------------- ----------------- ----------
    Exocrine                  41 (15)          237 (85)          
    Endocrine                 12 (41)          17 (59)           
  Age                                                            
    Exocrine                  45 ± 4.7         67.4 ± 9.3        \< 0.001
    Endocrine                 40.7 ± 7.6       64 ± 8.2          \< 0.001
  Location of tumor                                              
    Exocrine                                                     0.24
      Head of pancreas        30 (73)          142 (60)          
      Body/tail of pancreas   7 (17)           51 (21)           
      Unknown                 4 (10)           44 (19)           
    Endocrine                                                    0.84
      Head of pancreas        4 (33)           4 (24)            
      Body/tail of pancreas   5 (39)           8 (47)            
      Unknown                 3 (38)           5 (29)            
  Surgery performed                                              
    Exocrine                  7 (17)           41 (17)           0.97
    Endocrine                 4 (33)           10 (59)           0.23
  Chemotherapy                                                   
    Exocrine                  28 (68)          98 (42)           0.001
    Endocrine                 5 (42)           6 (35)            0.73
  Radiation therapy                                              
    Exocrine                  15 (37)          39 (17)           0.003
    Endocrine                 0                0                 
  Number still alive                                             
    Exocrine                  0 (0)            11 (5)            0.16
    Endocrine                 4 (33)           8 (47)            0.46
  Overall survival (months)                                      
    Exocrine                  9.6              11.2              0.64
    Endocrine                 74.3             47.6              0.19

Discussion {#s4}
==========

Successful treatment of an aggressive cancer warrants an aggressive approach \[[@R12]\]. Aggressive treatment can include multimodality therapy, more intensive therapy, or more invasive therapy. Surgical treatment of PanCA improves survival and post-surgical adjuvant therapy further modestly extends this result \[[@R13]-[@R16]\]. Completing PanCA treatment regimens is difficult but important to enhance survival. Higher utilization of therapy and better ability to tolerate intensive therapy would be expected to correlate with improved outcome. Young patients, in part because of fewer comorbidities, should be better able to withstand aggressive treatment.

Age is associated with the likelihood of completing therapy, but the role that age plays in PanCA survival is more complex \[[@R03]-[@R05], [@R17]-[@R19]\]. Younger patients are more likely to undergo surgical resection as well as adjuvant therapy \[[@R03]-[@R05], [@R20], [@R21]\]. Finlayson et al demonstrated that while older patients undergoing surgery had more comorbidities and a higher complication rate, 5-year survival did not differ from younger patients \[[@R10]\]. Others have shown increased survival in younger surgical patients \[[@R18]\]. Studies are also conflicting with regard to the effects of chemotherapy based on age \[[@R22]-[@R24]\]. These studies lack a uniform definition for old age. There is no agreement as to which age constitutes old and this is reflected in the literature. PanCA patients from ages 65 years to 80 years have been categorized as old \[[@R25]\].

We examined the distribution of age among PanCA patients to define young and old age for this study. Increasing comorbid conditions and worsening performance status with age are relative contraindications to aggressive treatment in older patients. We expected to find age-related survival differences due at least in part to differences in treatment administered. While younger patients in our study received more treatment for PanCA, they did not have improved OS compared to the older patients. As would be expected, we found exocrine PanCA was treated differently than endocrine PanCA \[[@R18]\]. Even among the PanCA subtypes, no OS difference was seen. Our data do not support that increased therapy in younger patients leads to improved outcomes.

The Ellis Fischel Cancer Center is the oldest cancer center west of the Mississippi River and opened its doors as the central hub of the Missouri state cancer program in 1949 \[[@R26]\]. Missouri cancer data are not captured by the SEER program; therefore, data reported in this study are unique from studies previously published from the SEER database. The longitudinal nature of this study can be considered both a strength and weakness. Data were collected from patients across many eras of PanCA treatment. None of the more recent innovations such as neoadjuvant therapy or FOLFIRINOX were available to patients in this study. Other limitations of the study include the small study size, particularly in the younger age group; therefore, non-significant findings should be interpreted cautiously.

We believe improvements in PanCA treatment rely on development of new therapies and techniques rather than more aggressive use of the currently available modalities. As such, neoadjuvant therapy is currently being widely studied both as a means to downstage tumors to improve chance of resectability as well as determine patients most likely to benefit from pancreatic resection \[[@R27]-[@R29]\]. Additionally, post-operative complications after pancreatic resection do not prevent adjuvant chemotherapy administration \[[@R30]\]. With newer and more aggressive therapies to augment surgical resection, survival may be improved. Promising new therapies include the addition of molecular target agents with currently used cytotoxic agents as well as immunotherapy combined with cytotoxic therapy \[[@R31]-[@R33]\].

Review of PanCA patients treated over the last quarter century at our cancer institute shows those ≤ 50 years old have a different histologic profile than those patients \> 50 years old, receive more treatment, but do not have better survival. Many problems with treating PanCA still exist. Too many patient are not candidates for treatment or do not receive treatment, the treatment options are harsh, treatment complications may prohibit completion of therapy and the treatments are not particularly effective. Thus, despite increased use of aggressive therapy in younger patients, outcomes are not better. Improvements in PanCA are dependent upon the future development of more effective therapy than bringing more patients to receive the currently available therapy.
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